Korro Bio (KRRO) EBITDA (2018 - 2026)
Korro Bio (KRRO) posted EBITDA of -$20.4 million for Q1 2026, up 59.45% on a QoQ basis from -$50.4 million in Q4 2025, and up 18.32% year-over-year from -$17.3 million in Q1 2025.
Korro Bio (KRRO) EBITDA (2018 - 2026) Analysis & Trends
Korro Bio's EBITDA history runs 9 years deep, the most recent figure standing at -$20.4 million for Q1 2026.
- Quarterly EBITDA rose 18.32% year-over-year to -$20.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$117.3 million (down 22.83% YoY) and the FY2025 annual result came in at -$121.9 million, down 32.58% from the prior year.
- EBITDA was -$20.4 million for Q1 2026 at Korro Bio, up from -$50.4 million in the prior quarter.
- Across five years, EBITDA topped out at $5.8 million in Q4 2022 and bottomed at -$50.4 million in Q4 2025.
- A 5-year average of -$22.2 million and a median of -$21.5 million in 2024 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2022 — EBITDA surged 127.19% — and 2023, when it plunged 563.03%.
- Korro Bio's EBITDA stood at $5.8 million in 2022, then plunged by 563.03% to -$26.9 million in 2023, then grew by 14.33% to -$23.0 million in 2024, then sank by 118.73% to -$50.4 million in 2025, then soared by 59.45% to -$20.4 million in 2026.
- Business Quant data shows KRRO's EBITDA at -$20.4 million in Q1 2026, -$50.4 million in Q4 2025, and -$19.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 472.68 Bn | 467.89 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 122.24 Bn | 114.99 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.33 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 55.93 Bn | 50.75 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.59 Bn | 34.58 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Korro Bio | 120.63 Mn | 6.66 Mn | - | -20.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.44 Mn |
| Dec 31, 2025 | -50.40 Mn |
| Sep 30, 2025 | -19.24 Mn |
| Jun 30, 2025 | -27.20 Mn |
| Mar 31, 2025 | -25.02 Mn |
| Dec 31, 2024 | -23.04 Mn |
| Sep 30, 2024 | -23.29 Mn |
| Jun 30, 2024 | -24.13 Mn |
| Mar 31, 2024 | -21.45 Mn |
| Dec 31, 2023 | -26.89 Mn |
| Sep 30, 2023 | -19.15 Mn |
| Jun 30, 2023 | -18.41 Mn |
| Mar 31, 2023 | -20.09 Mn |
| Dec 31, 2022 | 5.81 Mn |
| Sep 30, 2022 | -20.28 Mn |
| Jun 30, 2022 | -21.27 Mn |
| Mar 31, 2022 | -23.26 Mn |
| Dec 31, 2021 | -21.36 Mn |
| Sep 30, 2021 | -24.99 Mn |
| Jun 30, 2021 | -17.48 Mn |